Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting paclitaxel-induced neutropenia using the DMET platform.

Pharmacogenomics - 1 Jan 2015

Nieuweboer Annemieke J M, Smid Marcel, de Graan Anne-Joy M, Elbouazzaoui Samira, de Bruijn Peter, Martens John W, Mathijssen Ron H J, van Schaik Ron H N

Abstract excerpt

AIM: The use of paclitaxel in cancer treatment is limited by paclitaxel-induced neutropenia. We investigated the ability of genetic variation in drug-metabolizing enzymes and transporters to predict hematological toxicity. PATIENTS & METHODS: Using a discovery and validation approach, we identified a pharmacogenetic predictive model for neutropenia. For this, a drug-metabolizing enzymes and transporters plus DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neutropenia
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Membrane Transport Proteins

Share to Oligonucleotide Array Sequence Analysis

Share to Paclitaxel

Share to Predictive Value of Tests

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 26265135
DOI: 10.2217/pgs.15.68

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting paclitaxel-induced neutropenia using the DMET platform.PMID 26265135Read ↗

A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.Semantic proximity Read ↗

Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.Semantic proximity Read ↗

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.Semantic proximity Read ↗

High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial.Semantic proximity Read ↗

Germline pharmacogenetics of paclitaxel for cancer treatment.Semantic proximity Read ↗

Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical ImplicationsSemantic proximity Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.Semantic proximity Read ↗

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.Semantic proximity Read ↗

Pharmacogenomics-Driven Multimodal Data Integration Improves Predictions of Adverse Drug Reactions in Cancer Patients using Machine LearningSemantic proximity Read ↗

Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationshipsSemantic proximity Read ↗

ABCG2 genetic variant as risk factor for neutropenia in patients with metastatic or advanced hormone receptor -positive, HER2-negative breast cancer treated with palbociclibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.